Connect with us

Technology

ProLogium Shines Bright at CES 2025 with Fully Inorganic Electrolyte Battery Breakthroughs

Published

on

Five transformative breakthroughs are reflected in a CES keynote titled:

“Battery Breakthroughs: Redefining the EV Driving Experience”

LAS VEGAS, Jan. 7, 2025 /PRNewswire/ — At CES 2025 in Las Vegas—a premier event focused on sustainable transportation, AI, and smart city solutions, ProLogium Technology emerged as a standout with the debut of its fourth-generation lithium-ceramic battery (LCB) system. With five transformative breakthroughs, ProLogium directly addressed key EV market concerns: total cost of ownership, range anxiety, and safety.

Founder and chairman Vincent Yang joined FEV Global Vice President Dr. Thomas Hülshorst on the Mobility Stage to explore the future of EVs. Yang emphasized: “After launching the world’s first full-ceramic separator battery in 2024, ProLogium is once again leading in 2025 with the world’s first fully inorganic electrolyte battery, aiming to start pilot production and bring next-generation batteries to life by year-end.”

Fully Inorganic Electrolyte: A Milestone in Battery Technology

Years of research have culminated in ProLogium’s fourth-generation LCB battery with fully inorganic electrolyte, eliminating organic content entirely and increasing inorganic content from 90% to 100%. This small advancement greatly enhances energy density, charging speed, low-temperature reliability, and safety, redefining what next-generation batteries can achieve.

Redefining EV Driving with the Fourth-Generation LCB System

A 2024 McKinsey report highlighted total cost of ownership, range anxiety, and safety as the primary barriers to EV adoption. ProLogium’s fourth generation LCB system tackles these challenges head-on with five key advancements:

Extended range (powered by exceptional energy density);Refueling-like fast charging;Reliable low-temperature performance;Efficient heat dissipation; andUltimate safety.

Energy Density: Breaking New Barriers

ProLogium’s breakthroughs in energy density surpass lithium iron phosphate (LFP) batteries by 99%, 111%, and 150% over three years. The fourth-generation LCB achieves 380Wh/kg and 860–900Wh/L [Note1], significantly improving range, reducing costs, and enabling lighter, more efficient designs.

The system supports thick-film and bi-cell technologies, paving the way for further advancements in battery performance. “Building on our success, we’re nearing our 2026 target of surpassing 450Wh/kg and 1000Wh/L with lithium metal anodes,” said Yang, referencing the company’s latest lab results.

Refueling-Like Fast Charging

The fourth-generation LCB system cuts charging time to just 4 minutes for 60% capacity and 6 minutes for 80% [Note2]. This rapid charging mirrors the convenience of refueling, while boosting charging station efficiency and profitability.

Reliable Cold-Weather Performance

ProLogium’s battery excels in extreme cold, with 2–3 times the ionic conductivity of traditional liquid batteries at room temperature. Even at -20°C, it delivers consistent range performance, eliminating concerns about unpredictable driving distances in harsh conditions.

Safe and Safer: Eliminating Combustible Gas Risks

Unlike conventional lithium-ion or sulfide-based batteries, ProLogium’s fully inorganic electrolyte is inherently non-flammable, even under extreme heat or voltage. An advanced Active Safety Mechanism (ASM) further prevents thermal runaway by activating automatically at high temperatures.

In rigorous overcharge tests—including 300°C, 5C, 20V, and 250% capacity—the battery remained fireproof and non-combustible, achieving a Hazard Level of 2–3. These advancements set a new benchmark for safety in next-generation batteries.

Rapid Heat Dissipation and Stable Performance

ProLogium’s ceramic separator and advanced wet film coating technology deliver three times the thermal conductivity of traditional liquid batteries. Large-format cell designs (200–500 × 560 mm) enhance heat dissipation, ensuring stability even under high-load conditions like high-speed driving. Additionally, the planar liquid cooling system reduces reliance on active cooling, lowers activation frequency, and improves overall energy efficiency.

Driving Industry Value and Building a Sustainable Ecosystem

At CES 2025, Yang and Dr. Hülshorst delivered a keynote titled: “Battery Breakthroughs: Redefining the EV Driving Experience”

Yang stressed: “True innovation begins with the core chemistry of batteries—reducing charging times and enhancing safety to benefit the entire ecosystem. The EV market can only thrive sustainably when consumers trust battery technology and charging stations operate profitably.”

Dr. Hülshorst added: “ProLogium’s high-energy-density cells enable smaller, lighter battery packs, ideal for EVs. By combining ProLogium’s forward-thinking technology with FEV’s engineering expertise, we are shaping the future of sustainable transportation.”

ProLogium’s commitment to sustainability includes a circular system achieving over 80% material recovery, enhancing the value of second-hand vehicles.

“EVs shouldn’t just be an option—they should represent a better future,” Yang concluded. “From consumers to operators, manufacturing to recycling, ProLogium is creating an ecosystem that delivers value at every level, advancing the global vision of a net-zero future.”

Note 1:
The third-generation lithium-ceramic battery achieves 359Wh/kg and 811Wh/L, providing a benchmark for the fourth-generation’s advancements.

Note 2:
The third-generation lithium-ceramic battery fast charges from 5% to 60% in 5 minutes and 5% to 80% in 8.5 minutes.

About ProLogium: ProLogium Technology was founded in 2006 and is an innovative company specializing in the development and manufacturing of next-generation lithium-ceramic batteries. ProLogium offers advanced solutions for electric vehicles, consumer markets, and industrial applications. Its proprietary technologies are protected by over 900 international patents (both granted and under review). The company has delivered more than 12,000 lithium-ceramic battery samples to global automakers for testing and the development of modules.

ProLogium’s first gigawatt-hour scale production demonstration line, located in Taoyuan, Taiwan, began production in 2024 to serve the global market. In May 2024, ProLogium announced the opening of its first overseas R&D center, located in Paris-Saclay, dedicated to developing solutions tailored to the European market. At the same time, ProLogium’s first overseas gigafactory project, located in Dunkirk, France, successfully completed the public consultation process to obtain construction and environmental assessment permits. Construction is expected to begin in 2025, with mass production slated for 2027. 

 

 

View original content:https://www.prnewswire.com/news-releases/prologium-shines-bright-at-ces-2025-with-fully-inorganic-electrolyte-battery-breakthroughs-302344974.html

SOURCE ProLogium Technology

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Danaher Announces Investment Partnership in Innovaccer Inc.

Published

on

By

Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions.Investment aligns with Danaher’s mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

WASHINGTON, Jan. 9, 2025 /PRNewswire/ — Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE: DHR) (“Danaher”), a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company.

Innovaccer has built a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, seeks to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

“Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need,” said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

“Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time,” said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. “We’re excited to connect our innovation ecosystem with Innovaccer’s to enable this healthcare transformation.”

“At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities,” said Abhinav Shashank, cofounder and CEO of Innovaccer. “We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions.”

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

FORWARD-LOOKING STATEMENTS 
Statements in this release that are not strictly historical, including any statements regarding events or developments that Danaher believes or anticipates will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. 

View original content:https://www.prnewswire.com/news-releases/danaher-announces-investment-partnership-in-innovaccer-inc-302347452.html

SOURCE Danaher Corporation

Continue Reading

Technology

SynCardia Systems Receives Decision to Grant First Patent in China for the Emperor Next-Generation Total Artificial Heart

Published

on

By

TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ — SynCardia Systems, LLC (“SynCardia”, or the “Company”), a Picard Medical, Inc. company, and the global leader in total artificial heart technology, is pleased to announce that the China National Intellectual Property Administration (“CNIPA”) has notified the Company of the administration’s decision to grant SynCardia its first patent covering the Company’s next-generation total artificial heart. This patent describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle.

This milestone represents a significant step toward realizing SynCardia’s vision of a fully implantable total artificial heart (“Emperor”), providing a life-saving solution to patients suffering from advanced heart failure worldwide. The next-generation Emperor artificial heart design builds upon SynCardia’s proven total artificial heart technology, with innovations aimed at improving patient outcomes and expanding accessibility to life-saving cardiac support.

“We are thrilled to receive this notification from CNIPA, as it reaffirms the global impact of our mission to advance our artificial heart technology,” said Patrick NJ Schnegelsberg, CEO of SynCardia Systems. “This patent is a crucial component of our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China.”

SynCardia remains committed to pioneering advancements in its artificial heart technology and expanding its reach to new markets. The Company continues to work closely with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.

About SynCardia Systems, LLC

SynCardia Systems, LLC is a leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart (“STAH”), which is the only U.S. Food and Drug Administration and Health Canada approved artificial heart[1]. The STAH has been used by over 2,100 patients worldwide.

Forward Looking Statements

This press release contains statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by the use of future dates or words such as “aim,” “vision,” “strategy,” “remain,” “or “continue” or the negative of such terms and other comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, risks, and uncertainties that could cause actual results to differ materially from such estimates or forecasts. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information in this press release. Such forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release except as required by law. Forward-looking statements in this press release may include, for example, statements about:  the patent’s ability to eliminate external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle, the vision of a fully implantable total artificial heart, improving patient outcomes and expanding accessibility to life-saving cardiac support, our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China and our continued work with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.

For media inquiries or further information, please contact the SynCardia Marketing Department via email marketing@syncardia.com.

Media Contact:
Marketing Department
Marketing@syncardia.com
520-545-1234

The SynCardia temporary Total Artificial Heart (the TAH-t) is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.

View original content:https://www.prnewswire.com/news-releases/syncardia-systems-receives-decision-to-grant-first-patent-in-china-for-the-emperor-next-generation-total-artificial-heart-302347516.html

SOURCE SynCardia Systems, LLC

Continue Reading

Technology

Amid California Wildfires, eNavvi Mobilizes Unlimited Prescription Credits for Healthcare Providers

Published

on

By

LOS ANGELES, Jan. 9, 2025 /PRNewswire/ — In response to the widespread fires currently devastating Los Angeles and surrounding areas, eNavvi today announced it will provide unlimited prescription credits to physicians across the state of California. This initiative is aimed at reducing logistical barriers to essential medications during an active emergency, enabling healthcare professionals to quickly prescribe and route medications to patients in need. 

eNavvi offers unlimited prescription credits to physicians across California in response to widespread fires.

“eNavvi is designed for emergency responsiveness. We strongly believe that access to prescriptions and medications should never be an issue when dealing with far more important matters.” 
— Dr. Simon Chang, CEO, eNavvi 

Keeping Healthcare Accessible in Times of Crisis 

With wildfires severely impacting local infrastructure and preventing many patients from accessing their usual pharmacy or medical facilities, eNavvi is stepping in to fill a critical gap. The company’s proprietary digital platform allows providers to submit prescriptions and refills from any location, ensuring consistent medication access for patients during this emergency. By offering unlimited credits for prescription routing, eNavvi removes usage constraints so physicians can focus on patient care. 

Key features of eNavvi’s emergency support initiative include: 

Unlimited Prescription Credits for Providers: All California physicians have unrestricted access to eNavvi’s prescribing platform at no additional cost.Statewide Availability: Physicians and patients across California can access the program, ensuring consistent and reliable medication delivery.Streamlined Digital Platform: eNavvi’s user-friendly interface allows physicians and patients to manage prescriptions from the safety of their homes or temporary shelters.

“Our goal is to ensure that healthcare access is never compromised,” said Dr. Reddy Pathakota, CFO, eNavvi. “We are proud to stand shoulder-to-shoulder with the brave first responders, physicians, and volunteers who are on the ground, putting their lives at risk for the safety of our communities.” 

How to Utilize Unlimited Prescription Credits 

Physicians Enroll with eNavvi: Register or log in to the eNavvi portal to confirm unlimited credit status. Submit Prescriptions as Needed: Providers can route an unlimited number of prescriptions and refills for patients in affected areas. Delivery or Pickup Options: Once routed, prescriptions may be delivered via mail-order (where available) or picked up at a partnering pharmacy.

Physicians or patients seeking immediate assistance can reach out to eNavvi’s email contact@enavvi.com for guidance. 

About eNavvi 

eNavvi is a leading digital healthcare platform focused on delivering efficient, affordable, and accessible prescriptions to patients nationwide. By leveraging advanced technology and strategic partnerships, eNavvi streamlines the pharmacy experience and empowers individuals to take control of their health. Whether during routine care or the midst of a crisis, eNavvi aims to reduce barriers to essential medications and provide critical support to communities in need. 

For more information, please visit www.enavvi.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-california-wildfires-enavvi-mobilizes-unlimited-prescription-credits-for-healthcare-providers-302347522.html

SOURCE eNavvi

Continue Reading

Trending